Infliximab Reverses Suppression of Cholesterol Efflux Proteins by TNF-α: A Possible Mechanism for Modulation of Atherogenesis

@inproceedings{Voloshyna2014InfliximabRS,
  title={Infliximab Reverses Suppression of Cholesterol Efflux Proteins by TNF-α: A Possible Mechanism for Modulation of Atherogenesis},
  author={Iryna Voloshyna and Sangeetha Seshadri and Kamran Anwar and Michael J. Littlefield and Elise Belilos and Steven E. Carsons and Allison B Reiss},
  booktitle={BioMed research international},
  year={2014}
}
Tumor necrosis factor- (TNF-) α is a proinflammatory proatherogenic cytokine. Infliximab, an anti-TNF-α monoclonal antibody, is effective in treating rheumatoid arthritis. However, its impact on cardiovascular burden and lipid transport is unclear. The present study investigates the effect of TNF-α and infliximab on reverse cholesterol transport (RCT) proteins. Uptake of modified lipoproteins by macrophages in the vasculature leads to atherogenic foam cell formation. RCT is mediated by proteins… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Antiatherogenic effects of Vitamin E against lead acetate induced hyperlipidemia

Majeda A. J. Alqayim
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND

Plasma IL-33 in atopic patients correlates with pro-inflammatory cytokines and changes cholesterol transport protein expression: a surprising neutral overall impact on atherogenicity.

  • Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 49 REFERENCES

H

Z. Szekanecz, G. Kerekes
  • Dér et al., “Accelerated atherosclerosis in rheumatoid arthritis,” Annals of the New York Academy of Sciences, vol. 1108, pp. 349–358
  • 2007
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

and S

H. Maradit-Kremers, P. J. Nicola, C. S. Crowson, K. V. Ballman
  • E.Gabriel, “Cardiovascular death in rheumatoid arthritis: a population-based study,” Arthritis and Rheumatism, vol. 52, no. 3, pp. 722–732
  • 2005
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Resveratrolmediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARγ and adenosine,

I. Voloshyna, O.Hai, M. J. Littlefield, S. Carsons, andA.B. Reiss
  • European Journal of Pharmacology,
  • 2013
VIEW 1 EXCERPT

and D

S. C. Kim, E. Yelin, C. Tonner
  • H. Solomon, “Changes in use of disease modifying anti-rheumatic drugs for rheumatoid Arthritis in the U.S. for the period 1983–2009,” Arthritis Care & Research, vol. 65, no. 9, pp. 1529–1533
  • 2013
VIEW 1 EXCERPT

and J

T. Dervieux, M. E. Weinblatt, A. Kivitz
  • M. Kremer, “Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 72, no. 6, pp. 908–910
  • 2013

Epigallocatechin - 3gallate prevents TNFαinduced NFκ B activation thereby upregulating ABCA 1 via the Nrf 2 / Keap 1 pathway in macrophage foam cells

Z.-C. Mo J. Jiang, K. Yin
  • International Journal of Molecular Medicine
  • 2012

K

J. Jiang, Z.-C. Mo
  • Yin et al., “Epigallocatechin-3-gallate prevents TNF-α-induced NF-κB activation thereby upregulating ABCA1 via the Nrf2/Keap1 pathway in macrophage foam cells,” International Journal of Molecular Medicine, vol. 29, no. 5, pp. 946–956
  • 2012